<ul>
<li>诺和诺德的 Akero Therapeutics 收购目标是艾利 Lilly 的领先产品</li>
</ul>
<p>Septerna, Inc. (NASDAQ:SEPN - 免费报告) - HC Wainwright 的股票研究人员在 1 月 20 日星期二发布的报告中下调了对 Septerna 2025 财年每股收益 (EPS) 的预期。HC Wainwright 分析师 R. Selvaraju 现在预计该公司将发布每股收益为（$1.53），低于之前预测的（$1.45）。HC Wainwright 对该股票给予 &#34;买入&#34; 评级，目标价为 $35.00。市场普遍预计 Septerna 当前全年的每股收益为（$7.11）。HC Wainwright 还对 Septerna 2025 年第四季度的每股收益预期为（$0.16），2026 年第一季度的每股收益预期为（$0.25），2026 年第二季度的每股收益预期为（$0.34），2026 年第三季度的每股收益预期为（$0.47），2026 年第四季度的每股收益预期为（$0.61），以及 2026 财年的每股收益预期为（$1.67）。</p>
<p>SEPN 也成为其他几份研究报告的主题。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Septerna 股票的 &#34;卖出 (d-)&#34; 评级。Raymond James Financial 于 12 月 19 日星期五对 Septerna 开始覆盖。他们对该股票给予了 &#34;强烈买入&#34; 评级，目标价为 $38.00。富国银行在 11 月 14 日星期五将 Septerna 的评级从 &#34;持平&#34; 上调至 &#34;超配&#34;，并将其目标价从 $18.00 提升至 $28.00。Truist Financial 于 12 月 15 日星期一对 Septerna 股票开始覆盖。他们给予了 &#34;买入&#34; 评级，目标价为 $34.00。最后，华尔街 Zen 在 1 月 10 日星期六的研究报告中将 Septerna 股票的评级从 &#34;强烈买入&#34; 下调至 &#34;买入&#34;。一位分析师对该股票给予了强烈买入评级，五位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;适度买入&#34;，平均目标价为 $33.83。</p>
<ul>
<li>分析师认为这些股票的价值可能翻倍</li>
</ul>
<p><strong>查看我们关于 Septerna 的最新研究报告</strong></p>
<h2>Septerna 股票下跌 2.5%</h2>
<p>Septerna 股票在星期四开盘价为 $26.35。该公司的 50 日移动平均价格为 $26.56，200 日移动平均价格为 $19.60。该股票的市值为 $11.8 亿，市盈率为 -17.45，贝塔值为 3.85。Septerna 的 12 个月低点为 $4.17，12 个月高点为 $30.50。</p>
<ul>
<li>现在是买入诺和诺德股票的时机吗？</li>
</ul>
<p>Septerna (NASDAQ:SEPN - 获取免费报告) 最近在 11 月 10 日星期一发布了季度收益数据。该公司报告的每股收益为（$0.09），低于市场普遍预期的 $0.19，差距为（$0.28）。该季度的收入为 $2150 万美元，而市场普遍预期为 $2450 万美元。Septerna 的净利润率为 -266.77%，股本回报率为 -17.98%。</p>
<h2>机构投资者对 Septerna 的看法</h2>
<p>几家机构投资者和对冲基金最近买入和卖出了该公司的股票。拉塞尔投资集团在第三季度收购了 Septerna 的新股份，价值约 $36,000。Covestor Ltd 在第三季度将其在 Septerna 的持股增加了 55.8%。Covestor Ltd 现在拥有 3620 股该公司的股票，价值 $68,000，此前在此期间又收购了 1296 股。法国巴黎银行金融市场在第三季度将其在 Septerna 的持股增加了 88.0%。法国巴黎银行金融市场现在拥有 4155 股该公司的股票，价值 $78,000，此前在上个季度又收购了 1945 股。摩根大通在第二季度将其在 Septerna 的持股增加了 15.0%。摩根大通现在拥有 10101 股该公司的股票，价值 $107,000，此前在上个季度又收购了 1315 股。最后，PharVision Advisers LLC 在第二季度收购了价值约 $107,000 的 Septerna 新股份。</p>
<h2>Septerna 的内部买卖情况</h2>
<p>在其他消息中，SVP Daniel D. Long 在 11 月 10 日星期一以每股平均价格 $18.06 出售了 3501 股该股票，总交易额为 $63,228.06。出售后，该高级副总裁直接持有该公司 92911 股股票，价值约 $1,677,972.66。这代表了其持股的 3.63% 的减少。该交易已在提交给 SEC 的文件中披露，可以通过此超链接访问。内部人士持有该公司 4.30% 的股票。</p>
<h2>关于 Septerna</h2>
<p>(获取免费报告)</p>
<p>我们是一家临床阶段的生物技术公司，开创了 G 蛋白偶联受体 (GPCR) 口服小分子药物发现的新纪元，依托我们专有的 Native Complex Platform™。我们的工业规模平台旨在释放 GPCR 治疗的全部潜力，并导致我们深厚的产品候选管道的发现和开发，最初专注于治疗三个治疗领域的患者：内分泌学、免疫学和炎症，以及代谢疾病。GPCR 是细胞膜受体中最大和最具多样性的家族，调节人类身体几乎每个器官系统的生理过程。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更喜欢的五只股票比 Septerna 更好</li>
<li>华尔街警报：买入 AES</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>新黄金价格目标</li>
<li>特朗普做了什么？？</li>
<li>融化警告</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Septerna 吗？</h2>
<p>在考虑 Septerna 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Septerna 并不在名单上。</p>
<p>虽然 Septerna 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>HC Wainwright 已将 Septerna, Inc. (NASDAQ:SEPN) 的 2025 财年每股收益 (EPS) 预估从 ($1.45) 下调至 ($1.53)。分析师维持 “买入” 评级，目标价为 $35.00。市场普遍预期 Septerna 全年每股收益为 ($7.11)。该股票的评级各异，包括一项强烈买入、五项买入和一项卖出。Septerna 的股票开盘价为 $26.35，下跌 2.5%，市值为 11.8 亿美元。最近的季度财报显示每股亏损 ($0.09)，未能达到预期</p>

<ul>
<li>Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead</li>
</ul>
<div class="lb-trans"><ul>
<li>诺和诺德的 Akero Therapeutics 收购目标是艾利 Lilly 的领先产品</li>
</ul>
</div><p>Septerna, Inc. (NASDAQ:SEPN - Free Report) - Equities researchers at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for shares of Septerna in a report issued on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($1.53) for the year, down from their previous forecast of ($1.45). HC Wainwright has a &#34;Buy&#34; rating and a $35.00 price objective on the stock. The consensus estimate for Septerna's current full-year earnings is ($7.11) per share. HC Wainwright also issued estimates for Septerna's Q4 2025 earnings at ($0.16) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.61) EPS and FY2026 earnings at ($1.67) EPS.</p>
<div class="lb-trans"><p>Septerna, Inc. (NASDAQ:SEPN - 免费报告) - HC Wainwright 的股票研究人员在 1 月 20 日星期二发布的报告中下调了对 Septerna 2025 财年每股收益 (EPS) 的预期。HC Wainwright 分析师 R. Selvaraju 现在预计该公司将发布每股收益为（$1.53），低于之前预测的（$1.45）。HC Wainwright 对该股票给予 &#34;买入&#34; 评级，目标价为 $35.00。市场普遍预计 Septerna 当前全年的每股收益为（$7.11）。HC Wainwright 还对 Septerna 2025 年第四季度的每股收益预期为（$0.16），2026 年第一季度的每股收益预期为（$0.25），2026 年第二季度的每股收益预期为（$0.34），2026 年第三季度的每股收益预期为（$0.47），2026 年第四季度的每股收益预期为（$0.61），以及 2026 财年的每股收益预期为（$1.67）。</p>
</div><p>SEPN has been the topic of several other research reports. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Septerna in a research report on Wednesday, October 8th. Raymond James Financial initiated coverage on Septerna in a report on Friday, December 19th. They issued a &#34;strong-buy&#34; rating and a $38.00 price objective on the stock. Wells Fargo &amp; Company raised Septerna from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and lifted their target price for the stock from $18.00 to $28.00 in a report on Friday, November 14th. Truist Financial initiated coverage on shares of Septerna in a research report on Monday, December 15th. They issued a &#34;buy&#34; rating and a $34.00 target price for the company. Finally, Wall Street Zen lowered shares of Septerna from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, January 10th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average target price of $33.83.</p>
<div class="lb-trans"><p>SEPN 也成为其他几份研究报告的主题。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Septerna 股票的 &#34;卖出 (d-)&#34; 评级。Raymond James Financial 于 12 月 19 日星期五对 Septerna 开始覆盖。他们对该股票给予了 &#34;强烈买入&#34; 评级，目标价为 $38.00。富国银行在 11 月 14 日星期五将 Septerna 的评级从 &#34;持平&#34; 上调至 &#34;超配&#34;，并将其目标价从 $18.00 提升至 $28.00。Truist Financial 于 12 月 15 日星期一对 Septerna 股票开始覆盖。他们给予了 &#34;买入&#34; 评级，目标价为 $34.00。最后，华尔街 Zen 在 1 月 10 日星期六的研究报告中将 Septerna 股票的评级从 &#34;强烈买入&#34; 下调至 &#34;买入&#34;。一位分析师对该股票给予了强烈买入评级，五位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;适度买入&#34;，平均目标价为 $33.83。</p>
</div><ul>
<li>Analysts Think These Stocks Could More Than Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为这些股票的价值可能翻倍</li>
</ul>
</div><p><strong>Check Out Our Latest Research Report on Septerna</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Septerna 的最新研究报告</strong></p>
</div><h2>Septerna Stock Down 2.5%</h2>
<div class="lb-trans"><h2>Septerna 股票下跌 2.5%</h2>
</div><p>Septerna stock opened at $26.35 on Thursday. The company's 50-day moving average price is $26.56 and its two-hundred day moving average price is $19.60. The stock has a market cap of $1.18 billion, a P/E ratio of -17.45 and a beta of 3.85. Septerna has a twelve month low of $4.17 and a twelve month high of $30.50.</p>
<div class="lb-trans"><p>Septerna 股票在星期四开盘价为 $26.35。该公司的 50 日移动平均价格为 $26.56，200 日移动平均价格为 $19.60。该股票的市值为 $11.8 亿，市盈率为 -17.45，贝塔值为 3.85。Septerna 的 12 个月低点为 $4.17，12 个月高点为 $30.50。</p>
</div><ul>
<li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>现在是买入诺和诺德股票的时机吗？</li>
</ul>
</div><p>Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.28). The company had revenue of $21.50 million during the quarter, compared to the consensus estimate of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%.</p>
<div class="lb-trans"><p>Septerna (NASDAQ:SEPN - 获取免费报告) 最近在 11 月 10 日星期一发布了季度收益数据。该公司报告的每股收益为（$0.09），低于市场普遍预期的 $0.19，差距为（$0.28）。该季度的收入为 $2150 万美元，而市场普遍预期为 $2450 万美元。Septerna 的净利润率为 -266.77%，股本回报率为 -17.98%。</p>
</div><h2>Institutional Investors Weigh In On Septerna</h2>
<div class="lb-trans"><h2>机构投资者对 Septerna 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. acquired a new stake in Septerna during the third quarter worth about $36,000. Covestor Ltd lifted its holdings in shares of Septerna by 55.8% during the 3rd quarter. Covestor Ltd now owns 3,620 shares of the company's stock worth $68,000 after acquiring an additional 1,296 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Septerna by 88.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company's stock worth $78,000 after acquiring an additional 1,945 shares in the last quarter. JPMorgan Chase &amp; Co. increased its stake in Septerna by 15.0% in the second quarter. JPMorgan Chase &amp; Co. now owns 10,101 shares of the company's stock valued at $107,000 after acquiring an additional 1,315 shares during the last quarter. Finally, PharVision Advisers LLC acquired a new position in Septerna during the second quarter valued at approximately $107,000.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买入和卖出了该公司的股票。拉塞尔投资集团在第三季度收购了 Septerna 的新股份，价值约 $36,000。Covestor Ltd 在第三季度将其在 Septerna 的持股增加了 55.8%。Covestor Ltd 现在拥有 3620 股该公司的股票，价值 $68,000，此前在此期间又收购了 1296 股。法国巴黎银行金融市场在第三季度将其在 Septerna 的持股增加了 88.0%。法国巴黎银行金融市场现在拥有 4155 股该公司的股票，价值 $78,000，此前在上个季度又收购了 1945 股。摩根大通在第二季度将其在 Septerna 的持股增加了 15.0%。摩根大通现在拥有 10101 股该公司的股票，价值 $107,000，此前在上个季度又收购了 1315 股。最后，PharVision Advisers LLC 在第二季度收购了价值约 $107,000 的 Septerna 新股份。</p>
</div><h2>Insider Buying and Selling at Septerna</h2>
<div class="lb-trans"><h2>Septerna 的内部买卖情况</h2>
</div><p>In other news, SVP Daniel D. Long sold 3,501 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $18.06, for a total transaction of $63,228.06. Following the sale, the senior vice president directly owned 92,911 shares of the company's stock, valued at approximately $1,677,972.66. This represents a 3.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，SVP Daniel D. Long 在 11 月 10 日星期一以每股平均价格 $18.06 出售了 3501 股该股票，总交易额为 $63,228.06。出售后，该高级副总裁直接持有该公司 92911 股股票，价值约 $1,677,972.66。这代表了其持股的 3.63% 的减少。该交易已在提交给 SEC 的文件中披露，可以通过此超链接访问。内部人士持有该公司 4.30% 的股票。</p>
</div><h2>About Septerna</h2>
<div class="lb-trans"><h2>关于 Septerna</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.</p>
<div class="lb-trans"><p>我们是一家临床阶段的生物技术公司，开创了 G 蛋白偶联受体 (GPCR) 口服小分子药物发现的新纪元，依托我们专有的 Native Complex Platform™。我们的工业规模平台旨在释放 GPCR 治疗的全部潜力，并导致我们深厚的产品候选管道的发现和开发，最初专注于治疗三个治疗领域的患者：内分泌学、免疫学和炎症，以及代谢疾病。GPCR 是细胞膜受体中最大和最具多样性的家族，调节人类身体几乎每个器官系统的生理过程。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Septerna</li>
<li>Wall Street Alert: Buy AES</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>New gold price target</li>
<li>Trump Did WHAT??</li>
<li>Melt-up warning</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Septerna 更好</li>
<li>华尔街警报：买入 AES</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>新黄金价格目标</li>
<li>特朗普做了什么？？</li>
<li>融化警告</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Septerna Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Septerna 吗？</h2>
</div><p>Before you consider Septerna, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Septerna 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Septerna 并不在名单上。</p>
</div><p>While Septerna currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Septerna 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 对 Septerna 的盈利发布了负面预测